Replies to post #7677 on Vericel Corp. (VCEL)

[Giovinco]

yes no doubt, HC Wainwright analyst Swayampakula Ramakanth says HSGX still has reasonable chance of FDA approval, Histogenics' Phase 3 study of NeoCart for knee cartilage repair narrowly missed its primary endpoint, but he tells investors that not all hope is lost. Despite the disappointing topline result, NeoCart showed significant benefits over microfracture surgery in a number of secondary endpoints and would have met its primary endpoint using current FDA guidelines.